What does STOP-IgAN tell us about how to treat IgA nephropathy?
E Rutherford, Division of Cardiovascular and Diabetes Medicine, Medical Research Institute, Ninewells Hospital & Medical, School, Dundee DD1 9SY, UK. Email e.rutherford@dundee.ac.uk.
E
E
Rutherford
P B
PB
Mark
D004305:Dose-Response Relationship, Drug; D016903:Drug Monitoring / Q000379:methods; D005922:Glomerulonephritis, IGA / Q000175:diagnosis / Q000188:drug therapy / Q000276:immunology; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology; D007677:Kidney Function Tests / Q000379:methods; D015166:Monitoring, Immunologic; D010043:Outcome and Process Assessment, Health Care; D016032:Randomized Controlled Trials as Topic
D007166:Immunosuppressive Agents